If your gastroenterologist has prescribed Entyvio for ulcerative colitis and you have a Cigna plan, the short answer is that Cigna does cover Entyvio, but coverage is not automatic. Cigna treats Entyvio as a specialty biologic that requires prior authorization, a gastroenterologist's involvement, and documentation that you meet its published medical-necessity criteria. The good news is that Cigna's own coverage policy spells out exactly what it looks for, which means you can prepare the right paperwork before the request is even submitted. This guide walks through how Cigna's coverage works for Entyvio in ulcerative colitis, what prior authorization typically requires, and how to handle a denial.
What Entyvio Is and Why Cigna Treats It as Specialty
Entyvio, the brand name for vedolizumab, is an integrin receptor antagonist approved by the FDA for adults with moderately to severely active ulcerative colitis and Crohn's disease. It is gut-selective, meaning it blocks the alpha-4 beta-7 integrin that helps inflammatory cells travel into the intestinal lining, so its effect is concentrated in the digestive tract rather than the whole body. Treatment usually begins with intravenous infusions at weeks 0, 2, and 6, followed by maintenance dosing every eight weeks, with a subcutaneous 108 mg pen available every two weeks after the first two infusions. Because vedolizumab is expensive, provider-administered, and clinically complex, Cigna places it in the specialty category, which is what triggers prior authorization and specialty-pharmacy handling rather than a simple retail fill.
How Cigna, Express Scripts, and Accredo Fit Together
Cigna manages its pharmacy benefits through Express Scripts, its pharmacy benefit manager, and dispenses specialty biologics through Accredo, its specialty pharmacy. Cigna's member materials describe Accredo as the specialty pharmacy that fills and ships specialty medications and can deliver provider-administered drugs directly to a doctor's office. For an infused drug like intravenous Entyvio, this distinction matters. Depending on your plan, infused Entyvio may be billed under the medical benefit when it is administered in an infusion suite or office, while the self-injected subcutaneous pen is more likely to run through the pharmacy benefit and Accredo. Where the drug sits affects your cost share and which prior-authorization pathway applies, so it is worth asking Cigna which benefit your specific prescription falls under.
What Cigna's Prior Authorization Typically Requires
Cigna publishes separate coverage policies for the two formulations. For the infused version, the policy states that prior authorization is required and that initial approval is granted for six months when the patient is at least 18 and the medication is prescribed by or in consultation with a gastroenterologist. The subcutaneous policy adds an important hurdle: it notes that Entyvio subcutaneous requires the use of preferred products before approval, which is step therapy applied through Cigna's inflammatory conditions preferred specialty management policy. In practice this means your plan may ask you to have tried certain preferred biologics first, or to document why they are not appropriate. These criteria reflect Cigna's published policy rather than a guarantee for any individual plan, so always confirm the rules in your own plan documents.
Building a Strong Medical-Necessity Case
The fastest path to approval is giving the reviewer everything the policy asks for in the first submission. That starts with confirming a gastroenterologist is the prescriber or consultant, since Cigna's policy explicitly requires specialist involvement for initial approval. From there, the supporting record should align with how Cigna evaluates continued therapy. Its policy looks for objective evidence of benefit at reauthorization, listing examples such as fecal calprotectin, C-reactive protein, endoscopic assessment, or a reduced corticosteroid dose, alongside symptom improvement like decreased stool frequency or rectal bleeding. Documenting your baseline disease activity and any prior therapies before you start treatment gives your gastroenterologist the comparison points needed later. Society guidance also supports this choice of drug: the AGA living guideline for moderate-to-severe ulcerative colitis classifies vedolizumab among the higher-efficacy options and suggests it for biologic-naive patients over lower-efficacy alternatives.
How Entyvio Performs and Why That Supports Coverage
Coverage decisions lean on the evidence behind a drug, and Entyvio's pivotal data are well established. In the GEMINI 1 trial, vedolizumab produced a week 6 clinical response in 47.1 percent of patients compared with 25.5 percent on placebo, and at week 52 clinical remission was reached by 41.8 percent of those continuing every eight weeks versus 15.9 percent on placebo. That durable maintenance benefit is part of why guidelines place vedolizumab among preferred first-line biologics and why it is frequently a covered option on commercial formularies. When your appeal or initial request cites the policy criteria you meet, the specialist who prescribed it, and the established efficacy data, you give the reviewer a complete picture that maps directly onto what Cigna evaluates, which improves the odds of a smooth approval.
What to Do If Cigna Denies Coverage
A denial is common and rarely final. Read the denial letter closely, since it names the specific criterion that was not met, whether that is missing gastroenterologist documentation, an unmet step-therapy requirement, or insufficient evidence of disease severity. Your gastroenterologist can then file an appeal that supplies the missing piece, often through a peer-to-peer review where the prescriber speaks directly with a Cigna medical reviewer. If the internal appeal fails, you generally have the right to an external review by an independent third party. Throughout the process, keep copies of your records, lab results, and prior treatment history, because a well-documented case is the single biggest factor in turning a denial into an approval. Confirming your plan's exact timelines and required forms with Cigna keeps the appeal on track.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.